Task Specific Training for Advanced Multiple Sclerosis
ConditionMultiple Sclerosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHunter College of City University of New York
About this trial
The purpose of this study is to find effective physical therapy treatments for individuals who have severe multiple sclerosis. Physical therapy treatments for mild-to-moderate multiple sclerosis exists, however, very limited research has been done for physical therapy for severe multiple sclerosis (MS). In this study 10 participants diagnosed with severe MS will engage in 1-hour physical therapy sessions twice a week for 6 weeks to address limitations in standing, balancing, and bed mobility.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
definitive diagnosis of Multiple Sclerosis
Expanded Disability Status Scale (EDSS) of 7.0-8.0
Ability to read, understand , and sign an informed consent -
Disqualifiers
evidence of MS exacerbation in the 4 weeks prior to starting the study
any orthopedic, cardiopulmonary, or non-MS neurologic symptoms that will interfere with their ability to participate in the study
Trial design
Design model
Single group
Treatments tested in this trial
Task specific physical therapy
Other interventionPhysical Therapy based specifically on tasks that the participant os having difficulty with
Treatment groups
15 Participants
are divided into 1 treatment groupGroup A: Task specific Physical TherapyExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Multiple Sclerosis Physical Frailty Functional Assessment (MSPFFA)
Assessment of ability to perform functional mobility tasks. The MSPFFA is a 14 item ordinal scale; the maximum score is a 56, minimom score is 14. The higher the score, the better the function and the less physically frail the person being tested is considered to be.
Time frame
Will be administered twice, once at pre-intervention and once at post-intervention. The length of the intervention is 6 weeks.Secondary outcomes
1
Multiple Sclerosis Impact Scale-29 (MSIS29)
Self report measure of the impact of MS on the participant. The MSIS-29 is 29 item self report measure. The higher the score, the greater the impact of MS on the person person reporting bleives they have.The score is rated from 0-100 with the higher score indicating a greater impact on the individual from MS.
Time frame
Will be administered twice, once at pre-intervention and once at post-intervention. The length of the intervention is 6 weeks.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Hunter College of City University of New York
Lead sponsor
Multiple Sclerosis Foundation
Collaborator
Source ClinicalTrials.gov